Related Experiment Video
Updated: Mar 8, 2026
08:23
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
Published on: November 29, 2019
11.9K
Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis
Fereshteh Alsahebfosoul1,2, Ilnaz Rahimmanesh1,3, Mansour Shajarian1,4
1Isfahan Research Center of Multiple Sclerosis, Isfahan, Iran.
Biomolecular Concepts
|January 21, 2017
Summary
Interleukin-33 (IL-33) levels are elevated in multiple sclerosis (MS) patients, suggesting a role in disease development. Interferon beta treatment may reduce IL-33 levels in MS.
Area of Science:
- Immunology
- Neuroscience
- Biochemistry
Background:
- Cytokines play a role in the immunopathogenesis of multiple sclerosis (MS).
- Interleukin-33 (IL-33), an IL-1 superfamily member, is implicated in autoimmune disorders.
- Understanding cytokine roles in MS is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate plasma levels of IL-33 in relapsing-remitting MS (RRMS) patients.
- To compare IL-33 levels between RRMS patients and healthy controls.
- To assess the effect of interferon beta (IFN-β) treatment on IL-33 levels in MS.
Main Methods:
- A case-control study involving 44 RRMS patients and 44 healthy controls.
- Plasma samples were collected from participants.
- Interleukin-33 (IL-33) levels were quantified using ELISA.
Main Results:
- Significantly elevated plasma IL-33 levels were observed in RRMS patients compared to controls (p=0.005).
- IFN-β-treated MS patients exhibited lower IL-33 levels than untreated patients (p<0.001).
- Untreated patients showed higher IL-33 levels, suggesting a potential association with MS development.
Conclusions:
- Elevated IL-33 plasma levels may be associated with the development of MS.
- IL-33 could be a potential biomarker for MS.
- IFN-β treatment might modulate IL-33 levels in MS patients.
